What the New Psychedelic Therapy Executive Order Means for Baltimore Patients — and What Is Available Right Now
The psychedelic therapy executive order signed by President Trump on April 18, 2026 has generated significant attention — and significant questions. If you are a Baltimore patient living with treatment-resistant depression, PTSD, chronic pain, or severe anxiety, you may be wondering: what does this actually mean for you, right now? We want to answer that honestly, clearly, and without overpromising. The short answer: the executive order is a meaningful signal, but the treatments it accelerates are not yet available. What is available today — right now, at our Canton clinic — is already one of the most powerful psychedelic-adjacent therapies in medicine. This post explains both.
What the Psychedelic Therapy Executive Order Actually Does
On April 18, 2026, President Trump signed the psychedelic therapy executive order (White House — Full Text) directing federal agencies to remove bureaucratic barriers to a small group of psychedelic medicines that have already earned FDA “Breakthrough Therapy” designation — a category reserved for treatments showing meaningful promise in early trials for serious conditions.
In concrete terms, the order does four things:
- Priority Review Vouchers: The FDA Commissioner is directed to grant National Priority Vouchers to psychedelic drugs that have received Breakthrough Therapy designation — accelerating the agency’s formal review timeline.
- Right-to-Try expansion: A new pathway for eligible patients to access investigational psychedelic medicines — including ibogaine compounds — under existing Right-to-Try laws, before full FDA approval.
- DEA rescheduling reviews: The Attorney General is directed to initiate rescheduling reviews for compounds that successfully complete Phase 3 clinical trials, so reclassification can happen promptly after approval.
- $50 million in federal funding: HHS is directed to allocate at least $50 million through ARPA-H (White House Fact Sheet) to support state governments developing psychedelic medicine programs, clinical trial participation, and real-world evidence generation.
The medicines most directly affected include MDMA-assisted therapy for PTSD, psilocybin for treatment-resistant depression, and ibogaine — a plant-based psychoactive compound drawing significant interest for PTSD, addiction, and traumatic brain injury, particularly among veterans. FDA Commissioner Marty Makary announced that three serotonin 2a agonist psychedelics will receive priority review vouchers, with decisions expected as early as this summer. (STAT News)
Important context from Harvard Law’s Petrie-Flom Center: Legal scholars note that while the executive order sends a strong signal, much of its language still gives the FDA Commissioner considerable discretion. The order accelerates the pathway — it does not guarantee or define a specific timeline for any individual treatment reaching general clinical availability.
What the Psychedelic Therapy Executive Order Does Not Do
We want to be direct with you about this, because false hope is not something we are willing to offer.
The psychedelic therapy executive order does not make MDMA, psilocybin, or ibogaine available today. Even with expedited review, these compounds are not FDA-approved for general patient use. Real availability in licensed clinical settings is likely still one to several years away, depending on how Phase 3 trials conclude and how quickly the DEA rescheduling process proceeds.
The psychedelic therapy executive order draws particular attention to ibogaine, which has drawn intense public interest due to its reported benefits for veterans with PTSD — carries known safety concerns, including a risk of potentially fatal cardiac arrhythmias. Johns Hopkins’ Frederick Barrett, director of the Center for Psychedelic and Consciousness Research, noted that while the executive order could enable objective scientific study of ibogaine, the compound’s cardiovascular risks mean rigorous clinical oversight will be essential. (NBC News) Clinical availability will follow evidence — not presidential enthusiasm. (ABC News)
We mention this not to be discouraging — the executive order is genuinely significant — but because the psychedelic therapy executive order should not be a reason to delay treatment when real options exist today — we never want you to wait in silence for something that is years away when you are suffering now, and when something real and available may already be able to help.
Executive Order Treatments vs. What Is Available Now: Side-by-Side
The question we hear most often: “Is what the executive order is talking about the same as ketamine?” The table below answers that directly.
| Treatment | FDA Status | Available Now? | Conditions | Insurance |
|---|---|---|---|---|
| IV Ketamine Therapy | FDA-approved anesthetic; off-label psychiatric use | ✓ Yes — at Vita Nova Baltimore | TRD, PTSD, anxiety, OCD, bipolar depression, chronic pain, suicidal ideation | Out-of-network benefits may apply; free verification available |
| SPRAVATO® (Esketamine) | FDA-approved 2019 for TRD & MDSI | ✓ Yes — at Vita Nova Baltimore | Treatment-resistant depression, MDD with suicidal ideation | Often covered by insurance & Medicare Part D with prior authorization |
| Psilocybin | Breakthrough Therapy designation; Phase 3 trials ongoing | ⏳ Not yet — accelerated by EO | Treatment-resistant depression (trials); legal in OR & CO only | Not covered — not FDA-approved |
| MDMA | Breakthrough Therapy designation; Phase 3 trials ongoing | ⏳ Not yet — accelerated by EO | PTSD (primary focus of trials) | Not covered — not FDA-approved |
| Ibogaine | Schedule I; early human trials; EO directs DEA rescheduling review | ✗ Not available in US clinics | PTSD, addiction, TBI (early research only) | Not covered — Schedule I controlled substance |
What Is Already Available While You Wait: Ketamine Therapy in Baltimore
While the psychedelic therapy executive order points toward future treatments, there is already an FDA-supported psychedelic-adjacent therapy that has been quietly helping people with treatment-resistant depression, PTSD, and chronic pain for years — and it is available right now at Vita Nova in Baltimore’s Canton neighborhood: ketamine infusion therapy and SPRAVATO® (esketamine).
Ketamine and esketamine work on the same NMDA glutamate receptor system that researchers believe underlies the therapeutic effects of psilocybin and other psychedelics — promoting rapid neuroplasticity, loosening the grip of entrenched thought patterns, and creating an opening for healing and insight. For many patients, relief begins within hours to days, not the weeks or months required by traditional antidepressants.
Two FDA-Supported Options Available Now at Vita Nova Baltimore
IV Ketamine Infusion Therapy
Pharmaceutical-grade ketamine administered intravenously in a medically monitored private treatment room. Effective for treatment-resistant depression, anxiety, PTSD, OCD, chronic pain, and more. Most patients notice meaningful improvement within 24–72 hours of their first infusion. Supervised by Dr. Joshi’s clinical team.
Learn about IV ketamine therapy →
SPRAVATO® (Esketamine) Nasal Spray
The only FDA-approved nasal spray specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Insurance often covers SPRAVATO® for eligible patients. Administered in-clinic under the supervision of Suzanne, our SPRAVATO® and psychiatric specialist. Vita Nova is a REMS-certified SPRAVATO® provider.
Learn about SPRAVATO® treatment →
How Ketamine Relates to the Psychedelic Therapy Executive Order Movement
To understand where ketamine fits in the context of the psychedelic therapy executive order: ketamine is often described separately from psychedelics, but its mechanism of action — and the therapeutic experience it produces — overlaps meaningfully with what researchers observe in psilocybin and MDMA-assisted therapy. All of these compounds, in clinical settings, appear to promote a similar outcome: a temporary loosening of rigid mental patterns that allows new perspectives, emotional processing, and neural rewiring to occur.
The difference is regulatory status. Ketamine has been FDA-approved since 1970. SPRAVATO® received FDA approval in 2019. Psilocybin, MDMA, and ibogaine are still in clinical trials. The executive order aims to narrow that gap — but ketamine and esketamine are already on the right side of it. For clinical context on treatment-resistant depression, see the NIMH overview of depression.
This is why the psychedelic therapy executive order, for all its significance, doesn’t change what we recommend for patients who are suffering today. The most evidence-backed, most accessible, and most immediately available form of this class of therapy is already here.
Conditions This Matters For — Right Now
While the psychedelic therapy executive order points toward future availability, if you are in Baltimore living with any of the following, ketamine or SPRAVATO® may already be a viable option right now — no waiting required:
Treatment-Resistant Depression
Anxiety Disorders
Depression with Suicidal Ideation
Ketamine for Suicidal Depression →
SPRAVATO® for Suicidal Ideation →
Chronic Pain
Bipolar Depression
Addiction Recovery
About Vita Nova — Who We Are
Vita Nova Ketamine & Wellness Clinic has been delivering ketamine infusion therapy and SPRAVATO® in Baltimore since 2023. We are LegitScript certified, and we have cared for more than 200 patients. Our clinical team includes Dr. Joshi’s team for ketamine infusion therapy, and Suzanne, our dedicated SPRAVATO® and psychiatric specialist.
Every treatment takes place in a calm, private, medically monitored environment. We are not a volume practice. We are a specialty clinic that takes the time your nervous system needs. We also offer NAD+ IV therapy and a full range of IV wellness treatments as part of our holistic approach to recovery and resilience.
We do not believe in waiting for perfect when good is available now. The psychedelic therapy executive order signed this week is a signal that the medical community, and now the federal government, is taking seriously what many of our patients have told us for years: that these medicines, delivered thoughtfully and in the right clinical setting, can offer relief when nothing else has.
A Conversation, Not a Commitment
If you have been holding on — trying another medication, another therapist, another protocol, hoping something will finally break through — we understand how exhausted you are. We also want you to know that the psychedelic therapy executive order aside, you do not have to wait for future approvals to explore whether a real, available, evidence-based therapy might help you right now.
The most useful next step is a conversation, not a commitment. We offer consultations — available in-person at our Canton clinic or via secure telemedicine — where you can ask questions, share what you have tried, and learn what treatment would actually look like for your specific situation. There is no pressure to decide anything in that conversation.
Whatever you decide, we hope this week’s news brings you a little more hope that something better is possible — because it is, and some of it is already here.
Ready to Explore What’s Available Today?
Ketamine infusion therapy and SPRAVATO® are available now at Vita Nova in Canton, Baltimore — no waiting for future approvals. Free insurance verification available.
Frequently Asked Questions
Does the executive order mean I can access psilocybin or MDMA therapy now?
Not yet. The psychedelic therapy executive order accelerates FDA review and creates pathways for eligible patients under Right-to-Try, but MDMA, psilocybin, and ibogaine are not FDA-approved for general clinical use. Actual availability in licensed clinics like ours is likely still one to several years away depending on how clinical trials conclude.
Is ketamine the same as the psychedelics in the psychedelic therapy executive order?
Ketamine is not classified as a classic psychedelic, but it shares meaningful overlap in mechanism and therapeutic effect. It acts on NMDA glutamate receptors to rapidly promote neuroplasticity — a similar process to what researchers observe with psilocybin. The critical difference is that ketamine and esketamine (SPRAVATO®) are already FDA-approved and clinically available today.
What is SPRAVATO® — and is it related to the psychedelic therapy executive order?
The psychedelic therapy executive order focuses on compounds still in trials, but SPRAVATO® (esketamine) is already the FDA-approved nasal spray form of ketamine, specifically indicated for treatment-resistant depression and MDD with acute suicidal ideation. It is covered by many commercial insurance plans and Medicare Part D for these indications. Vita Nova handles the prior authorization process at no charge — submit your insurance information here.
What does ketamine therapy feel like — is it like the psychedelic therapy executive order treatments?
Ketamine shares therapeutic overlap with the medicines targeted by the psychedelic therapy executive order. Most patients describe mild dissociation during the infusion — a dreamlike, floating sensation with altered perception of time. These effects fully resolve within 30–60 minutes of the session ending. Our clinical team remains present throughout. Many patients describe the experience as deeply meaningful and, in itself, therapeutic.
Where is Vita Nova located and how do I get started?
Vita Nova Ketamine & Wellness Clinic is at 513 Bayview Blvd, Baltimore, MD 21224 in the Canton neighborhood near Johns Hopkins Bayview Medical Center. We serve patients from across the Baltimore metro area including Towson, Ellicott City, Columbia, Annapolis, and beyond. Call (443) 563-1059 or book a consultation online.
Related resources: Ketamine Therapy Overview | SPRAVATO® Overview | Ketamine vs. SPRAVATO® | Mental Health Conditions | Ketamine for Mental Health Guide | SPRAVATO® Treatment Guide | FAQs
